RHOJ and cancer: We use structure-based virtual screening and molecular dynamics simulations (De Vivo et al., 2016) to identify compounds that putatively bind to the RHOJ/CDC42 effector interaction interface, measure the selective activity of these compounds against cancer cell lines and tumors, and demonstrate that they bind to CDC42 and inhibit CDC42 effector interactions.